SEC Form 4 · accession 0001603289-26-000002
AVITA Medical, Inc. · RCEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael E Tarnoff
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 4, 2026 · 7:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001762303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 6, 2025 | A | 26,250 | — | A | 26,250 | D | |
| Common StockF3,F2 | Jan 20, 2026 | A | 22,214 | — | A | 48,464 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F4,F5 | $5.36 | Aug 6, 2025 | A | 19,063 | A | — | Aug 6, 2035 | Common Stock | 19,063 | 19,063 | D |
| Stock Options (Right to Buy)F6 | $3.77 | Jan 20, 2026 | A | 16,133 | A | Jan 20, 2027 | Jan 20, 2036 | Common Stock | 16,133 | 16,133 | D |
Explanation of responses
- F1Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F2Includes unvested RSUs
- F3Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F4On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F5These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.
- F6On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.